RENOPROTECTIVE PROPERTIES OF NOVEL ANTI-DIABETIC AGENTS

Abstract

Chronic Kidney Disease (CKD) is the steady loss of renal function over time.   CKD can also constitute abnormalities in the kidney structure. Kidney damage is measured using albuminuria, structural abnormalities, electrolytes and other abnormalities, prior kidney transplant or a projected glomerular filtration rate (eGFR) <60 mL/min/1.73 m [1]. Even though CKD has no known cure, its advancement can be slowed down by regulating the risk factors like high blood glucose levels, high blood pressure and dyslipidemia [2]. According to Mohamed et al. [3] diabetes accounts for almost 44% of all new CKD cases; this means that approximately 1 in 3 patients with diabetes also have kidney disease.  For this reason, this investigation was chosen to analyze the agents that can regulate blood glucose levels while having renoprotective effects that have been shown to be enormously beneficial in this patient group.

References

1. Andrassy KM. Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013 Sep; 84(3): 622–23. [doi: 10.1038/ki.2013.243] [PMID: 23989362]
2. Leite KM, Long AM, Ostroff ML, Borges L, Braden G. A review of the renoprotective effects of novel Antidiabetic Agents. J Pharm Pract. 2021 Feb; 34(1): 141–8. [doi: 10.1177/089719002090234] [PMID: 32067559]
3. Mohamed RH, Sedky AA, Hamam GG, Elkhateb L, Kamar SA, Adel S, et al. Sitagliptin's renoprotective effect in a diabetic nephropathy model in rats: The potential role of PI3K/AKT pathway. Fundam Clin Pharmacol. 2022 Apr;36(2):324-37. [doi: 10.1111/fcp.12736] [PMID: 34735026]
4. Krishnan A, Shankar M, Lerma EV, Wiegley N, GlomCon Editorial Team. Kidney Med. 2023 Feb;5(4):100608. [doi: 10.1016/j.xkme.2023.100608] [PMID: 36915368]
5. Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol (Lausanne). 2019 Jun;10: 389. [doi: 10.3389/fendo.2019.00389] [PMID: 31275246]
6. Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 Receptor Agonists and Kidney Protection. Medicina (Kaunas). 2019 May;55(6): 233. [doi: 10.3390/medicina55060233] [PMID: 31159279]